CJC-1295 *without DAC* (modified GRF 1-29) is a sermorelin analog with four amino-acid substitutions improving stability against DPP-4 cleavage but no albumin tether. No standalone human RCT of modGRF 1-29 has been published — its clinical claims are extrapolated from the DAC variant (Teichman 2006, Ionescu 2006) and from sermorelin's GHRH(1-29) literature. Mechanistically a near-certainty; cleanly characterized clinically, no.
0 human studies · 4 animal studies
Four aa substitutions (D-Ala, Gln, Ala, Leu) extend half-life vs. sermorelin from minutes to hours.
No published human RCT of modGRF 1-29 alone — practice is built on extrapolation.
Combined with ipamorelin (GHRP) it produces synergistic GH pulses, the basis for the 'CJC + ipamorelin' protocol.
Top citations
Ionescu 2006 — DAC variant pulsatility (mechanistic anchor)
Khorram 1997 — Sermorelin RCT (analog reference)
Our take
Mechanistically sound, clinically under-characterized. Treat any specific outcome claim for modGRF 1-29 alone as an extrapolation, not data.